This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
Enticott, P. G., Kennedy, H. A., Zangen, A., & Fitzgerald, P. B. (2011). The journal of ECT, 27(1), 41-43.
This case report examines the effect of Brainsway® Deep TMS (transcranial magnetic stimulation) in a patient with autism. In the case report, high-frequency stimulation was administered for 15 minutes per session, 9 treatments over 11 days. In this patient, social and interpersonal communications abilities were improved following treatment, as noted both by the patient and by her family. The conclusions were that Deep Transcranial Magnetic Stimulation in ASD can improves several facets of cortical dysfunction.